Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method

Magdalena Korecka,^a Michal J. Figurski,^a Susan M. Landau,^b Magdalena Brylska,^a Jacob Alexander,^a Kaj Blennow,^{c,d} Henrik Zetterberg,^{c,d,e,f} William J. Jagust,^b John Q. Trojanowski,^{a,g} and Leslie M. Shaw^{a,*}
for the Alzheimer's Disease Neuroimaging Initiative[†]

BACKGROUND: Cerebrospinal fluid (CSF) amyloid- β_{1-42} (A β 42) reliably detects brain amyloidosis based on its high concordance with plaque burden at autopsy and with amyloid positron emission tomography (PET) ligand retention observed in several studies. Low CSF A β 42 concentrations in normal aging and dementia are associated with the presence of fibrillary A β across brain regions detected by amyloid PET imaging.

METHODS: An LC-MS/MS reference method for A β 42, modified by adding A β 40 and A β 38 peptides to calibrators, was used to analyze 1445 CSF samples from ADNIGO/2 participants. Seventy runs were completed using 2 different lots of calibrators. For preparation of A β 42 calibrators and controls spiking solution, reference A β 42 standard with certified concentration was obtained from EC-JRC-IRMM (Belgium). A β 40 and A β 38 standards were purchased from rPeptide. A β 42 calibrators' accuracy was established using CSF-based A β 42 Certified Reference Materials (CRM).

RESULTS: CRM-adjusted A β 42 calibrator concentrations were calculated using the regression equation Y (CRM-adjusted) = $0.89X$ (calibrators) + 32.6. Control samples and CSF pools yielded imprecision ranging from 6.5 to 10.2% (A β 42) and 2.2 to 7.0% (A β 40). None of the CSF pools showed statistically significant differences in A β 42 concentrations across 2 different calibrator lots. Comparison of A β 42 with A β 42/A β 40 showed that the ratio improved concordance with

concurrent [18 F]-florbetapir PET as a measure of fibrillar A β ($n = 766$) from 81 to 88%.

CONCLUSIONS: Long-term performance assessment substantiates our modified LC-MS/MS reference method for 3 A β peptides. The improved diagnostic performance of the CSF ratio A β 42/A β 40 suggests that A β 42 and A β 40 should be measured together and supports the need for an A β 40 CRM.

Introduction

The 42 amino acid form of A β , A β 42, is a well characterized biomarker for brain amyloidosis associated with Alzheimer disease (AD) (1). Pathological changes of A β 42 are reflected in lowered concentrations in cerebrospinal fluid (CSF) and its deposition in amyloid plaques in the brain (2–4). CSF A β 42 concentrations show high concordance with plaque burden at autopsy (5, 6) and cortical amyloid ligand retention in positron emission tomography (PET) brain scans (7–10).

Two shorter A β forms, A β 40 and A β 38, have also been measured in CSF by liquid chromatography with tandem mass spectrometric (LC-MS/MS) detection or immunoassays (11–15). Similar to A β 42, they are produced by A β precursor protein catabolism by the concerted actions of β -secretase (BACE1) and the γ -secretase protease complex (16). One hypothesis posits that the concentration of A β 42 in CSF depends on the

^a Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ^b Helen Wills Neuroscience Institute, University of California, Berkeley, CA; ^c Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; ^d Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; ^e Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; ^f UK Dementia Research Institute at UCL, London, UK; ^g Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA.

* Address correspondence to this author at: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce St,

Philadelphia, PA 19104. Fax 215-662-7529; e-mail les.shaw@uphs.upenn.edu.

[†] Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.

A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Received June 25, 2019; accepted November 20, 2019.

DOI: 10.1093/clinchem/hvaa012

total amount of A β peptides present in addition to the pathophysiological A β status (17). By normalizing to the concentration of A β 40, the most abundant in the CSF, the ratio normalizes the differences in overall A β concentration, providing a better index of A β -related pathology. Recently, several studies reported that adding the CSF A β 42/A β 40 ratio to diagnostic tools might: (a) improve prediction accuracy of amyloid plaque burden in patients with mild cognitive impairment (MCI), (b) improve discrimination of AD from other forms of dementia, and (c) increase the concordance between CSF and PET amyloidosis (7, 13, 17).

We developed an LC–MS/MS method for A β 42 analysis in CSF (18). This published method was subsequently transferred to more sensitive mass spectrometer, fully validated and recognized as a reference method by the JCTLM (ID no. C12RMP1). Full method validation included suitability assessment of a surrogate matrix for calibrator preparation and an interlaboratory study in addition to fundamental parameters like accuracy, precision, sensitivity, and selectivity. This reference method was modified by adding 2 A β peptides, A β 40 and A β 38, as additional calibrators, and used for analysis of 1445 CSF samples from the ADNIGO/2 projects. One lot of in-house calibrators was analyzed against CRM-based calibration curve and the resulting linear regression equation used to obtain accuracy-based concentrations of A β 42 for ADNI samples.

In this paper we: (a) present the overall performance of our modified reference method and unique data for calibrators' lot-to-lot reproducibility, (b) describe value transfer from CRMs to calibrators, (c) discuss the results of A β peptides in ADNIGO/2 participants CSF, and (d) discuss the utility of the A β 42/A β 40 ratio for improved detection of amyloid plaque burden measured with PET.

Materials and Methods

ADNI STUDY PARTICIPANT DATA

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (19). The ADNI was launched in 2004 as a public-private partnership, led by principal investigator, Michael W. Weiner, MD and has undergone several phases (ADNI1, ADNIGO, ADNI2, and currently ADNI3). The primary goal of ADNI is to test whether serial magnetic resonance imaging, PET, other biological markers, and clinical and neuropsychological assessments can be combined to measure the progression of MCI to early AD. Clinical diagnoses were based on the absence (NC) or presence of a significant memory concern (EMCI, MCI, SMC, AD) together with meeting cut-off scores for the Mini-Mental State Examination (MMSE), Clinical Dementia Rating, and

Logical Memory tests as defined in the ADNI2 protocol (20). CSF samples obtained from ADNIGO/2 participants ($n = 1445$; ADNI2 $n = 1089$, ADNIGO $n = 151$, and ADNI1 $n = 205$ as part of longitudinal studies) were collected, processed according to ADNI2 Procedure Manual (20) and stored at -80°C . The range of storage times for CSF samples varied from 0.39 to 11.32 years (mean $\pm$ SD: 4.91 ± 2.07 years). Only aliquots which underwent a single freeze-thaw cycle prior to assay, were analyzed. Concurrent florbetapir amyloid PET results were available for 766 participants: 149 normal control (NC), 405 MCI, 87 subjective memory complaints (SMC), 125 AD (time interval of PET and LP $\pm$ 3 months for 762 participants, and between 98 and 154 days for 4 participants).

Florbetapir (FBP) images consisted of 4×5 min frames acquired at 50–70 minutes postinjection that were realigned, averaged, resliced to a common voxel size (1.5 mm^3), and smoothed to a common resolution of 8 mm^3 full-width at half maximum. MPRAGE images, acquired concurrently with baseline florbetapir images, were used as a structural template to define cortical composite regions (frontal, cingulate, temporal, parietal) and whole cerebellum (white + gray matter) in native space for each individual using Freesurfer (v.5.3.0) (21).

Baseline cortical summary florbetapir standardized value uptake ratios (SUVRs) were calculated by averaging across Freesurfer-defined cortical composite regional SUVR means, and dividing by the Freesurfer-defined whole cerebellum. An FBP positivity threshold of 1.11 was applied based on uptake in young, cognitively normal individuals (22) and which was autopsy-validated (23).

These studies were approved by the Institutional Review Boards, and written informed consent was obtained from all participants or authorized representatives.

CHEMICALS AND REAGENTS

The method used in this study is a modification of the published LC–MS/MS methodology (18) and of the JCTLM reference method, suitable for analysis of 2 additional A β peptides, A β 40 and A β 38. Therefore, we describe the changes made to the previously published protocol, and JCTLM reference method and summarize it in online Supplemental Table 1.

CSF A β 42 reference standard and CRMs were obtained from EC-JRC-IRMM (Belgium). An assigned value for A β 42 concentration in the reference standard was based on amino acid analysis (24). A β 42 concentrations in 3 CSF-based CRMs (450, 720, and 1220 pg/mL; uncertainty 70, 110, and 180 pg/mL, respectively) were measured by LC–MS/MS reference methods (18, 25). A β peptides, A β 40 and A β 38 (their concentrations

established by amino acid analysis [personal communication]) together with 3 internal standards, A β 42, A β 40, and A β 38, uniformly labeled with ^{15}N , were purchased (rPeptide). Two stock solutions of each A β peptide (500 and 50 ng/mL), for calibrators and quality control (QC) sample spiking solutions, were prepared by diluting the reference standard solution with DMSO and using an analytical balance to correct their final concentrations. The necessity of calibrator preparation on the balance was based on the experiment where 2 groups of calibrators used to measure A β 42 concentrations in 3 pooled CSF samples were prepared with and without an analytical balance. For this experiment fresh lot of calibrators was prepared each day ($n = 3$ days) and each sample was analyzed 3 times per day against 2 different sets of calibrators (prepared with and without the analytical balance).

Calibrators and QC samples used for analysis of ADNIGO/2 samples were prepared on the day of analysis in surrogate matrix by spiking 0.95 mL of the matrix (artificial CSF with 4% of BSA, [aCSF/BSA], online Supplemental Table 1) with 0.05 mL of spiking solution. Further details about calibrators/QC samples preparation are in online Supplemental Table 1 and in our previous paper (18). Each spiking solution for calibrators and QC samples contained 3 peptides at appropriate concentrations. Two different lots of calibrators were utilized for this project, no. 41717 (38 runs) and no. 92917 (32 runs).

Internal standards concentrations, 1 ng/mL, are lower than in the original protocol due to the more sensitive mass spectrometer used in this study. In addition to 3 surrogate matrix-QC samples, 5 pools of human CSF served as biological control samples.

SAMPLE PREPARATION AND CHROMATOGRAPHY WITH MASS SPECTROMETRIC DETECTION

There were no major changes in the sample preparation procedure (online Supplemental Table 1) aside from reduction of volumes of some compounds. Since analysis of A β peptides was carried out on the more sensitive XEVO TQ-S mass spectrometer (Waters), 2 changes were possible: (a) volume reduction of calibrators, QC and human CSF from 0.25 to 0.1 mL, and (b) injection volume decreased from 0.05 to 0.025 mL. The mass spectrometer was interfaced with an ACQUITY ultra performance liquid chromatograph (Waters), sample manager, 2 pumps, and column oven, as previously described (18). Online Supplemental Table 1 summarizes ion transitions for the 3 peptides, internal standards, and 2 qualifier ion transitions.

STUDY DESIGN

A β peptide imprecision and accuracy data were collected during 70 runs, and completed on 5 pairs of trap and

analytical columns (online Supplemental Table 1). QC samples (3 in aCSF/BSA and 3 pools) were analyzed in duplicate in each analytical run.

The modified reference method suitable for measurement of 3 A β peptides was re-validated by comparison with the reference method for analysis of A β 42 alone ($n = 79$ samples) and with the Elecsys $^{\text{®}}$ β -amyloid(1-42) immunoassay (Roche) ($n = 1439$ samples).

We used CSF-based CRM, from EC-JRC-IRMM, to establish the accuracy of A β 42 concentrations in one lot of our in-house calibrators for analysis of ADNIGO/2 samples. In 2 replicate runs, 7 A β 42 calibrators with A β 42 concentrations established by weight (C_A) were analyzed against the CRM-based calibration curve and relative concentrations (C_R) of A β 42 for all calibrators obtained by direct value transfer methodology (26). Linear regression analysis of C_A vs C_R resulted in a line that represents the relation of the concentrations of A β 42 in the CRMs and calibrators. Target A β 42 calibrator concentrations, C_T , were calculated from the regression equation:

$$C_T = \alpha \times C_R + b$$

where: C_T is the target concentration, α is the regression line slope, C_R – concentration of A β 42 obtained from CRM calibration curve, b is the regression line intercept.

The equation was also used for recalculation of A β 42 concentrations for ADNIGO/2 participants. New values for the A β 42 cut off and concordance with FBP PET were obtained.

STATISTICAL ANALYSES

Statistical analyses performed on the data collected during this long-term project include:

- assessment of imprecision and accuracy of measured concentrations of A β 42, A β 40, and A β 38 in 3 QC samples prepared in aCSF/BSA and 5 pools of human CSF
- comparison of A β 42 concentrations for 3 human CSF pools analyzed using 2 different lots of in-house calibrators to evaluate lot-to-lot reproducibility
- comparison of A β 42 concentrations obtained using the reference method (A β 42 alone) vs the modified method (3 A β peptides)
- comparison of A β 42 concentrations obtained using the modified method vs A β 42 results from the Elecsys β -amyloid (1-42) immunoassay
- assessment of the reference method stability based on A β 42 results for 46 replicates of one-freeze-thaw-cycle aliquots analyzed in 2014 vs 2017
- comparison of results between the 5 clinical cohorts: NC, early MCI (EMCI), MCI, SMC, and AD by unpaired t -test
- comparison of the concordance between FBP PET and CSF A β comparison of the concordance A β 42/A β 40 for ADNIGO/2 participants.

This is the first report of using CSF-based A β 42 CRMs for A β 42 concentration value transfer to in-house calibrators.

Results

ANALYTICAL METHOD EVALUATION

Imprecision and accuracy

For all 3 A β peptides interassay imprecision (CV) for all but one control participant (10.2 CV) was below 10% (online [Supplemental Table 2](#)). Importantly, for A β 42 concentrations below the cut-off value of approximately 1000 pg/mL, the CV was between 7.4 and 7.6% (based on QC 2 and Pool 58 with A β 42 concentrations of 778 and 935 pg/mL, respectively). Mean imprecision expressed as CV for duplicate analyses of the CSF samples was 4.5% (A β 42), 3.0% (A β 40), and 3.6% (A β 38).

Accuracy for all 3 A β peptides for control participants in aCSF/BSA was excellent, 97.5 to 103.1%. More details of the A β 40 method validation studies are in the online [Supplemental Data](#).

Lot-to-lot reproducibility

No statistically significant differences in A β 42 concentrations were found across 2 different lots of calibrators ($P = 0.767$, 0.256 , and 0.45 for each of 3 CSF pools) ([Fig. 1](#)). Our calibrators were prepared using an analytical balance since this preparation technique resulted in lower between days ($n = 3$) CV values for A β 42 concentrations in 3 human CSF pools compared to the data

obtained using calibrators prepared without analytical balance (3.3, 2.0, and 3.1% vs 7.4, 4.6, and 6.4%, respectively) (online [Supplemental Table 3](#)). This preparation procedure assured reproducibility of results across different lots of calibrators.

Method comparisons

A β 42 concentrations measured by the reference method (single analyte) and the modified reference method (triple analytes) showed a linear relationship, by Deming regression (27) with a correlation coefficient $r^2 = 0.96$, slope of 0.999 ($y = 0.999x + 13.46$), and mean error of 2.22% ($n = 79$) ([Fig. 2A](#)).

The regression plot between a highly automated method, Elecsys β -amyloid(1-42) immunoassay (28) and CRM-adjusted results also showed a linear relationship ($y = 0.913x + 73.63$) with r^2 of 0.92 and mean error of 1.30% ($n = 1439$) ([Fig. 2B](#)).

Method stability

Deming regression between 2 groups of results (2014 and 2017) showed excellent stability of our method over 3 years: correlation coefficient $r^2 = 0.93$ and mean error of 5% ([Fig. 3](#)). More details of the A β 40 method validation studies are in the online [Supplemental Data](#).

Standards accuracy check against A β 42 CRMs

Accuracy was 96.1–103.6% for CSF pools that assessed run quality where in-house calibrators were analyzed

against CRM-based calibration curve; mean accuracy was $94 \pm 3\%$ for the aCSF/BSA controls. Linear regression analysis established a line $y = 0.89x + 32.6$ (online Supplemental Fig. 1); all calibrator concentrations of A β 42 were recalculated to the new target values according to this equation.

This equation was also used to recalculate A β 42 concentrations for ADNIGO/2 participants and these new values were used to assess the A β 42, A β 42/A β 40 ratio cut offs, and concordance with FBP PET (Fig. 4).

CLINICAL UTILITY OF THE METHOD

CSF biomarkers for ADNIGO/2 samples, data overview
Concentrations of A β 42, A β 40, and the ratio A β 42/A β 40 in all ADNIGO/2 participant BASELINE CSF samples are summarized in Table 1. Statistical analyses revealed that A β 42 concentrations were significantly lower in the AD ($n = 130$), MCI ($n = 171$), and EMCI ($n = 268$) groups compared with NC ($n = 177$), as expected ($P < 0.0001$, $P < 0.0001$, and $P < 0.05$, respectively). In addition, A β 42 concentrations were significantly lower in AD vs MCI, EMCI, and SMC ($n = 95$) ($P < 0.0001$). A β 42 concentrations in AD and MCI, but not in EMCI ($P = 0.389$), were also significantly lower compared to NC ($P < 0.005$, $P < 0.05$). Furthermore, A β 40 concentrations were significantly lower in AD vs EMCI and SMC ($P < 0.05$ and $P < 0.005$, respectively) but not vs MCI ($P = 0.232$).

Values of the A β 42/A β 40 ratio in AD and MCI but not in EMCI were significantly lower compared with NC. In AD the ratio A β 42/A β 40 was significantly lower than the MCI, EMCI, and SMC groups ($P < 0.0001$).

There was no difference between A β 42, A β 40, and the A β 42/A β 40 ratios in the NC vs SMC ($P = 0.601$,

Table 1. The results of CSF biomarkers (A β 42, A β 40, and A β 42/A β 40) at BASELINE for ADNIGO/2 participants.

ADNIGO/2 participants	A β 42 (pg/mL) mean $\pm$ SD	A β 40 (pg/mL) mean $\pm$ SD	A β 42/A β 40 mean $\pm$ SD	n
Normal (NC)	1303 $\pm$ 573	8718 $\pm$ 2555	0.149 $\pm$ 0.05	177
EMCI	1167 $\pm$ 566	8506 $\pm$ 2518	0.138 $\pm$ 0.05	268
MCI	915 $\pm$ 434	8176 $\pm$ 2195	0.111 $\pm$ 0.05	171
AD	751 $\pm$ 397	7841 $\pm$ 2548	0.096 $\pm$ 0.03	130
SMC	1342 $\pm$ 581	8811 $\pm$ 2488	0.151 $\pm$ 0.05	95

t-test values. A β 42: $P < 0.0001$, < 0.0001 , and < 0.05 comparing NC to AD, MCI, and EMCI, respectively; $P < 0.0001$ for AD vs MCI, EMCI, and SMC. A β 40: $P < 0.005$, < 0.05 , and $P = 0.389$ for NC vs AD, MCI, and EMCI, respectively; $P < 0.05$, < 0.005 , and $P = 0.232$ for AD vs EMCI, SMC and MCI, respectively. A β 42/A β 40: $P < 0.0001$, < 0.0001 , < 0.05 for NC vs AD, MCI, and EMCI, respectively; $P < 0.0001$ for AD vs MCI, EMCI, and SMC. For NC vs SMC, $P = 0.601$, 0.773 , and 0.721 for A β 42, A β 40, and A β 42/A β 40, respectively. Abbreviations: EMCI—early MCI, SMC—subjective memory complaints.

0.773, and 0.721, respectively), consistent with a previous report using an automated immunoassay (10).

Concordance between amyloid PET and concentration of A β peptides in CSF

The relationships between CSF biomarkers and cortical florbetapir SUVRs are shown in Fig. 4. Based on this first-time analysis of ADNIGO/2 participant data by LC–MS/MS reference method, the concordance for A β 42 and florbetapir PET was 81%, and increased to 88% for the CSF A β 42/A β 40 ratio.

Mixture modeling analyses of A β 42 concentrations and A β 42/A β 40 ratio values provided the following cut-point values: 1096 pg/mL (A β 42) and 0.138 (A β 42/A β 40). ROC analysis using amyloid PET as the standard of truth afforded cut-off values of 992.9 pg/mL (A β 42) and 0.124 (A β 42/A β 40) (online Supplemental Figs. 2 and 3).

Frequency distribution histogram plots of A β 42 concentration and the A β 42/A β 40 ratio in 766 participants of ADNIGO/2 with cortical A β deposition, measured by florbetapir PET, are presented in Fig. 5. These plots show 2 overlapping distributions, PET-positive and PET-negative amyloid deposition. The A β 42/A β 40 ratio clearly better separates PET(+) from PET(–) participants, than A β 42 alone.

Discussion

In this paper we describe the analytical and clinical performance of a modified reference procedure for analysis of A β peptides in CSF by LC–MS/MS. We present data for the distribution of A β peptides and the A β 42/A β 40 ratio for ADNIGO/2 participants and based on statistical analyses we discuss the potential utility of the A β 42/A β 40 ratio for improved detection of amyloid pathology, which is important for accurate diagnosis of AD. We focused on A β 42, A β 40, and their ratio, however,

our modified method can assess the possible use(s) of A β 38 measurements in future studies. We also describe the procedure using A β 42 CRMs for assignment of target values of A β 42 concentrations for in-house calibrators.

This analysis of three CSF A β peptides was used for almost 5 months in 2017, employed 5 pairs of columns, analytical, and trapping, and two lots of in-house calibrators. The samples, calibrators, and QCs were analyzed weekly and the entire system was continuously operated Monday to Friday without need for between-run cleaning. This observation highlights the effectiveness of sample preparation and robustness of the entire system.

Based on this long-term experience we report that this procedure has very good characteristics for imprecision, accuracy, and duplicate measurement precision for all three A β peptides. Concentrations of A β 42 obtained by the modified method correlate very well with results obtained using both the reference method for A β 42 alone (slope 0.999, $r^2 = 0.96$), and Elecsys β -amyloid (1–42) immunoassay (29) (slope 0.913, $r^2 = 0.92$). The Elecsys β -amyloid (1–42) immunoassay calibrators were standardized to the same primary A β 42 standard material we used in this and another interlaboratory study (24) and this manufacturer worked collaboratively with others to study the commutability of CSF-based reference materials. These studies were of fundamental value to the work of producing the now-available CRMs (24, 30). There is an urgent need to harmonize assays across different platforms and this finding demonstrates the feasibility for success in this effort. In this paper, for the first time we describe reproducibility data for A β 42 concentration in CSF pools analyzed with two different lots of in-house calibrators. The stock solutions for A β 42 calibrators were prepared using an analytical balance for weighing both the primary standard material and diluent and the final concentrations corrected based on the obtained weight since, as described in Results,

we demonstrated that using an analytical balance improved reproducibility between different calibrator lots. This observation is critical at a time when efforts on developing reference systems for CSF biomarker measurements are in progress (31–33).

Forty-six samples had two Aβ42 concentration results, first from analyses in 2014 ADNI1 participant

samples and the second from the current project that included replicate aliquots for these samples as part of a longitudinal study. These data provided strong support for long-term method stability (slope 1.03, $r^2 = 0.93$). Lack of difference between the results from 2014 vs 2017 additionally supports documentation of lot-to-lot reproducibility and CSF sample stability.

In the clinical section of this study we describe for the first time profiles of A β peptides in 1445 ADNIGO/2 study participant CSFs and provide the incidence of Alzheimer pathologic change, defined as decreased CSF A β 42 concentration, or positive amyloid PET imaging test (34) across the AD, MCI, EMCI, SMC, and NC clinically diagnosed cohorts.

The CSF concentration of A β 40 for the AD and MCI group were also significantly lower compared to NC participants, while there was no statistically significant difference in CSF A β 40 concentration between AD and MCI. Decreased CSF concentration of A β 40 together with a discussion about the possible mechanisms of that change such as reduced neuronal numbers and/or viability were previously reported for patients with AD and non-AD patients when compared to control participants (35), and patients with frontotemporal dementia (36), vascular dementia, and dementia with Lewy bodies (37). Other studies examined CSF concentrations of A β 40 in AD and NC, but either found no significant differences (38) or A β 40 concentrations in the AD-MCI group turned out to be significantly higher compared to the control participants (14). More work is therefore required on A β 40 paying special attention to classification of participants and development of A β 40 reference material and method standardization.

As previously reported the CSF A β 42/A β 40 ratio is a better predictor of brain amyloid deposition in prodromal AD than CSF A β 42 alone and better differentiates AD dementia from non-AD dementias (7, 13, 17, 35, 39). Based on our finding in 766 ADNIGO/2 participants of improved concordance with PET from 81 to 88% we confirm these reports. Comparable concordance results were obtained using cutoffs based on ROC analysis (83 and 89% concordance values, respectively). Our method measures both peptides, A β 42 and A β 40 from the same sample minimizing methodological variability as a source of discordance between CSF and cortical amyloid. We suggest that these two peptides should both be measured and used for amyloid burden detection. For our study participants, the number of cases with abnormal/low A β 42 and normal PET (Fig. 4A; lower left quadrant) was higher than the number of cases with normal A β 42 and abnormal PET (Fig. 4A; upper right quadrant), consistent with previous reports (17). When the A β 42/A β 40 ratio was used as a diagnostic tool the number of cases with abnormal/low A β 42 and normal PET decreased by 43% (42 cases were moved to lower right quadrant; normal A β 42 and normal PET) (Fig. 4B), and the number of cases with normal A β 42 and abnormal PET dropped by 32% (16 cases were moved to the upper left quadrant; abnormal A β 42 and abnormal PET) (Fig. 4B). Thus, using the A β 42/A β 40 ratio improved concordance with amyloid PET for 7.6% of participants. A hypothesis-driven

explanation that the concentration of A β 42 in the CSF depends not only on the amyloid status of a given participant but also on the total amount of the A β peptides present has been described elsewhere (40). We tested for a possible influence of *APOE* ϵ 4 genotype on the concordance results and found (online Supplemental Figure 4), that participants with no ϵ 4 alleles had improved concordance for the ratio vs A β 42 alone, whereas the concordance values were comparable for participants with 1 or 2 alleles. Further studies are required to address the mechanistic basis for this observation.

In conclusion, the current study documents long-term analytical performance and substantiates the robustness of our modified LC-MS/MS reference method. We highlighted the needs for: (a) use of an analytical balance to maintain reproducibility between different lots of calibrators, (b) developing CRMs for A β 40, and (c) supporting the standardization process with the currently available three CRMs for A β 42 in CSF. From the clinical diagnostic perspective, these results for ADNIGO/2 participants show that the A β 42/A β 40 ratio improves concordance with amyloid PET.

Supplemental Material

Supplemental material is available at *Clinical Chemistry* online.

Nonstandard abbreviations: A β 42, amyloid b1-42; aCSF/BSA, artificial CSF with BSA; AD, Alzheimer disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; BSA, bovine serum albumin; CDR, clinical dementia rating; CRM, certified reference material; CSF, cerebrospinal fluid; CV, coefficient of variation; DMSO, dimethyl sulfoxide; EC-JRC, European Commission Joint Research Centre; EMCI, early MCI; FBP, florbetapir; IRMM, Institute for Reference Materials and Measurements; JCTLM, Joint Committee for Traceability in Laboratory Medicine; LC-MS/MS, liquid chromatography with tandem mass spectrometric detection; LP, lumbar puncture; MCI, mild cognitive impairment; MMSE, mini-mental state examination; MPRAGE, Magnetization Prepared Rapid Acquisition Gradient Echo; NC, normal controls; PET, positron emission tomography; QC, quality control; SMC, subjective memory complaints; SUVRs, standardized uptake value ratios

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

M. Korecka, statistical analysis; M.J. Figurski, statistical analysis; W.J. Jagust, financial support, administrative support; J.Q. Trojanowski, statistical analysis. L.M. Shaw provided statistical analysis.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: S.M. Landau, Cortexyme, NeuroVision; W.J. Jagust, Genentech, Novartis, Biogen; L.M. Shaw, Roche Diagnostics, Biogen.

Stock Ownership: None declared.

Honoraria: L.M. Shaw, Biogen.

Research Funding: Data collection/sharing for this project was funded by the ADNI (NIH Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development.

Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. S.M. Landau, NIH; L.M. Shaw, NIA/NIH ADNI study, U19AG024904.

Expert Testimony: None declared.

Patents: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation of manuscript, or final approval of manuscript.

References

1. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat Rev Neurol* 2010;6:131-44.
2. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ₄₂ in humans. *Ann Neurol* 2006;59:512-9.
3. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PIB and 18F-FDDNP binding. *J Nucl Med* 2009;50:1464-70.
4. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. *Neurology* 2009;73:1193-9.
5. Strozzyk D, Blennow K, White LR, Launer LJ. CSF Aβ₄₂ levels correlate with amyloid-neuropathology in a population-based autopsy study. *Neurology* 2003;60:652-6.
6. Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, et al. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the optima cohort. *J Alzheimer's Dis* 2015;44:525-39.
7. Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. *JAMA Neurol* 2017;74:1492-501.
8. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. *JAMA Neurol* 2014;71:1282-9.
9. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. *Ann Neurol* 2013;74:826-36.
10. Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's Dement* 2018;14:1470-81.
11. Lame ME, Chambers EE, Blatnik M. Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry. *Anal Biochem* 2011;419:133-9.
12. Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, et al. Reference measurement procedure for CSF amyloid beta (Aβ)₁₋₄₂ and the CSF Aβ₁₋₄₂/Aβ₁₋₄₀ ratio—a cross-validation study against amyloid PET. *J Neurochem* 2016;139:651-8.
13. Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Aβ₄₂/Aβ₄₀ and Aβ₄₂/Aβ₃₈ ratios: better diagnostic markers of Alzheimer disease. *Ann Clin Transl Neurol* 2016;3:154-65.
14. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. *J Alzheimer's Dis* 2014;43:183-91.
15. Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ₃₈, Aβ₄₀, and Aβ₄₂ in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. *J Alzheimer's Dis* 2013;33:1021-32.
16. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. *Neurobiol Aging* 2011;32:1090-8.
17. Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid Aβ₄₂/40 corresponds better than Aβ₄₂ to amyloid PET in Alzheimer's disease. *J Alzheimer's Dis* 2016;55:813-22.
18. Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M, et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(42) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. *JAD* 2014;41:441-51.
19. Alzheimer's disease Neuroimaging Initiative database. <http://www.adni.loni.usc.edu> (Accessed June 2018).
20. ADNI2 Clinical Protocols and Procedures Manuals. <http://www.adni.loni.usc.edu/methods/documents> (Accessed May 2018).
21. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. *J Nucl Med* 2013;54:70-7.
22. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Ann Neurol* 2012;72:578-86.
23. Clark CM, Schneider JA, Badell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ. Use of florbetapir-PET for imaging beta-amyloid pathology. *JAMA* 2011;305:275-83.
24. Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, et al. CSF Aβ₁₋₄₂—an excellent but complicated Alzheimer's biomarker—a route to standardisation. *Clin Chim Acta* 2017;467:27-33.
25. Leinenbach A, Pannee J, Dülfer T, Huber A, Bittner T, Andreasson U, et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid. *Clin Chem* 2014;60:987-94.
26. Blirup-Jensen S, Johnson AM, Larsen M. Protein standardization iv: value transfer procedure for the assignment of serum protein values from a reference preparation to a target material. *Clin Chem Lab Med* 2001;39:1110-22.
27. Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. <http://www.R-project.org/>
28. Shaw LM, Fields L, Korecka M, Waligorska T, Trojanowski JQ, Algranza D, et al. Method comparison of Aβ₁₋₄₂ measured in human CSF samples by liquid chromatography tandem mass spectrometry, the inno-Bia albio3 assay and the Elecsys[®] b-amyloid(1-42) assay. *Alzheimers Dement* 2016;12:668.
29. Bittner T, Zetterberg H, Teunissen C, Ostlund RE, Milotello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid(142) in human cerebrospinal fluid. *Alzheimers Dement* 2016;12:517-26.
30. Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, et al. Assessing the commutability of reference material formats for the harmonization of amyloid-beta measurements. *Clin Chem Lab Med* 2016;54:1177-91.
31. Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw

- LM, Zegers I, et al. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. *Biomarkers Med* 2012;6:401-7.
32. Zegers I, Schimmel H. To harmonize and standardize: making measurement results comparable. *Clin Chem* 2014;60:911-3.
33. Schimmel H, Zegers I. Performance criteria for reference measurement procedures and reference materials. *Clin Chem Lab Med* 2015;53:899-904.
34. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement* 2018;14:535-62.
35. Slaets S, Le Bastard N, Martin JJ, Slegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S. Cerebrospinal fluid A β 1-40 improves differential dementia diagnosis in patients with intermediate p-tau181p levels. *J Alzheimer's Dis* 2013;36:759-67.
36. Pijnenburg YA, Schoonenboom SN, Mehta PD, Mehta SP, Mulder C, Veerhuis R, et al. Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration. *J Neurol Neurosurg Psychiatry* 2006;78:735-7.
37. Spies PE, Slats D, Sjogren JM, Kremer BP, Verhey FR, Rikkert MG, Verbeek MM. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. *Curr Alzheimer Res* 2010;7:470-6.
38. Verbeek MM, De Jong D, Kremer HP. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. *Ann Clin Biochem* 2003;40:25-40.
39. Beaufils E, Dufour-Rainfray D, Hommet C, Brault F, Cottier JP, Ribeiro MJ, et al. Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the A β 42/A β 40 ratio. *J Alzheimer's Dis* 2013;33:775-80.
40. Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *World J Biol Psychiatry* 2018;19:244-328.